HGSOC patients with BRCA1/2 mutations show HRD and PARPi sensitivity. Notably, HRD and PARPi response can occur without BRCA mutations, suggesting other factors are involved. Loss of CCDC6 function can lead to HRD and PARPi sensitivity in HGSOC cells, making CCDC6 a potential therapeutic target and biomarker. Three CCDC6 missense mutations in HGSOC prompted investigation into their impact on HRD. Analyzing CCDC6 expression, localization and HRD data in the MITO16A trial aims to clarify the CCDC6-HRD relationship in a large cohort. The biochemical and morphological effects of CCDC6 mutants on the native protein were examined using pull-down assays and immunofluorescence. HR-reporter and cell viability assays determined the impact of these mutants on HRD and PARPi sensitivity. CCDC6 histochemical score and intracellular-localization were assessed in MITO16A samples after immunostaining and digitalization. CCDC6-mutated isoforms act as dominant-negative, preventing native CCDC6 nuclear translocation, disrupting RAD51 foci and HR-repair, and increasing PARPi sensitivity. In the MITO16A patient sample set, 66 of 185 (35%) showed barely detectable CCDC6 or nuclear exclusion ("CCDC6-inactive"). CCDC6 impairment in these "CCDC6-inactive" samples was associated with HRD in 75% (30/40) of suitable samples analyzed by the RAD51 test and in 52% (34/65) of suitable samples analyzed by genomic HRD testing, even in the presence of wild-type BRCA1/BRCA2 genes. The association between CCDC6 inactivity and HRD, both at genomic and functional level, occurred even in presence of wild-type BRCA1/BRCA2 genes, suggesting that CCDC6 may play a crucial role in DNA repair pathways independent of these well-known genes.
The progressive integration of Whole Slide Imaging (WSI) technology and Artificial Intelligence (AI) architectures is driving a structural transformation in pathology and precision oncology. This structured critical review analyzes and systematizes the impact of this technological transition along two fundamental operational dimensions of the modern biopharmaceutical industry: pre-registration Clinical Research and post-launch strategies governed by Medical Affairs. The first section explores how computational pathology is improving efficiency and reducing risk in drug development. Replacing analog visual assessment—intrinsically subject to inter-observer and intra-observer variability—with quantitative algorithms for cellular classification and segmentation enables optimization of patient recruitment in clinical trials, reducing screening failure rates. This review also examines the emerging role of Spatial Biology in extracting complex topological metrics from the Tumor Microenvironment (TME) and the use of AI for the objective and auditable quantification of critical surrogate endpoints, such as Pathological Complete Response (pCR), while acknowledging that algorithmic precision remains sensitive to pre-analytical variables and dataset biases. In the second section, the study investigates the strategic evolution of Medical Affairs, acting as a vital scientific communication and translational bridge between the complexity of Data Science and clinical hospital practice. Challenges related to AI adoption by clinicians are examined, emphasizing the importance of educational programs based on Explainable AI (XAI) to overcome the cognitive limitations of the black-box paradigm and the complex regulatory validation pathway for Software as a Medical Device (SaMD) under the stringent European IVDR framework—supported by an analysis of historical regulatory benchmarks such as the Paige Prostate case. The paper also explores the potential of AI in the large-scale generation of Real-World Evidence (RWE), applied to the creation of synthetic control arms in pharmacoeconomic settings. In conclusion, the study highlights that the diagnostic algorithm has ceased to be merely a laboratory support tool and has become a strategic asset and an integral adjunct to therapeutic decision-making. Overcoming current challenges related to data privacy through Federated Learning architectures, together with the imminent transition toward Foundation Models, foreshadows a fully data-driven healthcare ecosystem, making continuous skills development (digital upskilling) an essential requirement for professionals in the biopharmaceutical sector.
Figure S4: (A) Levels of endogenous CCDC6, MycCCDC6 WT and mutated isoforms overexpression were assessed in OVCAR3 and OV90 cells by Western Blot using an anti-CCDC6 antibody. Tubulin is shown as loading control. (B) Levels ofMyc-CCDC6 WT and mutated isoforms overexpression and the degree of CCDC6 silencing were assessed in OVCAR3 and OV90 cells by Western Blot using an anti-CCDC6 antibody. Tubulin is shown as loading control. (C-D) Following treatment with Etoposide [10 µM] for 8 hours, cell viability was assessed in OVCAR3 and OV90 cells (C) as well as in OVCAR3 and OV90 cells stably silenced for CCDC6 (shCCDC6) (D) transfected with the myc-tagged CCDC6 wild type (WT), the mutated isoforms, A226S, L2l 7P and P442S expression vectors, or the empty vector (EV). Error bars indicate the standard error mean derived from three independent experiments.
CCDC6-mutated isoforms form heterodimers with the CCDC6 WT protein and affect its intracellular distribution. A, List of myc-tagged CCDC6 mutants identified to date in HGSOC; schematic representation of the GFP-S-tag-CCDC6 WT construct and the S-protein agarose resin. B, S-tag pull-down of HeLa-Kyoto GFP-S-tag-CCDC6 and HeLa-Kyoto control cells, transfected with the myc-tagged CCDC6 mutants A226S, L217P, and P442S expression vectors or with the EV. Isolated proteins were immunoblotted with anti-myc and anti-GFP antibodies. The immunoblots of the whole cell lysates (WCL) with anti-myc, for transfection control, and anti-tubulin, as loading control, are shown at the bottom of the panel. C, Immunofluorescence images of HeLa-Kyoto GFP-S-tag-CCDC6 transfected with the myc-CCDC6 WT (e–h); the mutated isoforms A226S, L217P, and P442S expression vectors (i–t); or the EV as control (a–d). Nuclei are stained with Hoechst (blue channel). CCDC6 WT is shown as the endogenous GFP-S-tag-CCDC6 (green channel). The mutated isoforms were visualized by the anti-myc antibody (red channel). Quantification of the cytoplasmic-to-nuclear (Cyto/Nuclear) ratio of GFP-CCDC6 WT is shown on the right. Statistical significance was determined using one-way ANOVA (ns, not significant; ***, P < 0.001; ****, P < 0.0001). Colocalization metrics were computed using Pearson’s correlation coefficient (R) (values are reported in the table). D, The expression levels of CCDC6 (endogenous, GFP-tagged, and Myc-tagged forms) were assessed by Western blot using the anti-CCDC6 antibody. Tubulin is shown as a loading control.
Figure S5: Immunofluorescence images of OVCAR3 cells stably silenced for CCDC6 (shCCDC6) or control cells (shCTRL) transfected with the GFP vector (a-d) or the GFP-CCDC6 wild type (WT) co-transfected with the myc-tagged CCDC6 wild type (i-1), the mutated isoforms A226S, L217P and P442S expression vectors (m-x) or the empty vector (EV) as control (e-h). Nuclei are stained with Hoechst (Blue-channel). GFP-CCDC6 WT protein is shown in the green channel. The myc-tagged CCDC6 WT and mutated isoforms were visualized by the anti-myc antibody (red-channel).